ARYA Sciences Acquisition Corp IV
ARYD
NASDAQ Capital Market6.64
USD
-2.46
- -
CIK
0001838821
ISIN
KYG316591083
CUSIP
G31659108
Return %
Stock
S&P500
1Y
-38.06
26.53
3Y
-32.73
76.60
5Y
-40.34
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam Leo Stone
- Full Time Employees
- 3
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 51 Astor Place New York City NY United States of America 10003
- IPO Date
- Feb 26, 2021
- CIK
- 0001838821
- Website
- perceptivelife.com
- Similar Companies
- Business
- ARYA Sciences Acquisition Corp IV ARYA Sciences Acquisition Corp IV (Nasdaq:ARYD), a blank-check company sponsored by Perceptive Advisors, focuses on effecting mergers, share exchanges, or similar business combinations primarily with life sciences and medical technology companies in North America and Europe. Incorporated as a Cayman Islands exempted company in 2020 and headquartered in New York, the firm raised $130 million in its February 2021 initial public offering underwritten by Goldman Sachs and Jefferies, targeting innovative healthcare entities across the capital structure with its management team's expertise from Perceptive Advisors. As a special purpose acquisition company, it holds cash and cash equivalents pending deployment in a de-SPAC transaction, with no operational products or services prior to combination. In July 2024, ARYA Sciences Acquisition Corp IV completed a reverse merger with Adagio Medical, Inc., resulting in the formation of Adagio Medical Holdings, Inc., a developer of next-generation cardiac ablation technologies for treating atrial fibrillation; post-merger, ARYD shares were suspended from trading, marking the SPAC's dissolution and transition to the operating entity with an implied enterprise value of $113 million. This transaction followed the 2022 termination of a prior business combination agreement with Amicus Therapeutics, Inc. Amicus Therapeutics, Inc. for its gene therapy unit due to market conditions, extending ARYA IV's search timeline until its successful Adagio pairing. The deal underscores Perceptive Advisors' ongoing strategy in healthcare SPACs, building on prior successes like combinations with Immatics Biotechnologies and Cerevel Therapeutics.
Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies